Research programme: G protein-coupled receptor agonists - Arena Pharmaceuticals

Drug Profile

Research programme: G protein-coupled receptor agonists - Arena Pharmaceuticals

Latest Information Update: 30 Jul 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arena Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Obesity

Most Recent Events

  • 20 Apr 2007 Preclinical development is ongoing for small molecule compounds that mimic the agonist activity of niacin as ligands of G protein-coupled receptors
  • 02 Aug 2005 This programme is still in active development
  • 12 Jul 2004 Preclinical trials in Obesity in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top